Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| P2X Purinoceptor 3 (P2RX3) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| P2X Purinoceptor 3 (P2RX3) Products under Development by Stage of Development | 8 | 1 |
| P2X Purinoceptor 3 (P2RX3) Products under Development by Therapy Area | 9 | 1 |
| P2X Purinoceptor 3 (P2RX3) Products under Development by Indication | 10 | 1 |
| P2X Purinoceptor 3 (P2RX3) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 2 |
| P2X Purinoceptor 3 (P2RX3) Products under Development by Companies | 13 | 2 |
| P2X Purinoceptor 3 (P2RX3) Products under Development by Universities/Institutes | 15 | 2 |
| P2X Purinoceptor 3 (P2RX3) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 1 |
| Assessment by Molecule Type | 20 | 2 |
| P2X Purinoceptor 3 (P2RX3) Companies Involved in Therapeutics Development | 22 | 6 |
| Afferent Pharmaceuticals, Inc. | 22 | 1 |
| Asana BioSciences, LLC | 23 | 1 |
| Integral Molecular, Inc. | 24 | 1 |
| Neurim Pharmaceuticals Ltd | 25 | 1 |
| Pfizer Inc. | 26 | 1 |
| Shionogi &Co., Ltd. | 27 | 1 |
| P2X Purinoceptor 3 (P2RX3) Drug Profiles | 28 | 14 |
| AF-130 Drug Profile | 28 | 1 |
| AF-219 Drug Profile | 29 | 4 |
| ASN-009 Drug Profile | 33 | 1 |
| Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain Drug Profile | 34 | 1 |
| Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain Drug Profile | 35 | 1 |
| NEO-5937 Drug Profile | 36 | 1 |
| OSX-300 Drug Profile | 37 | 1 |
| OSX-300 Backups Drug Profile | 38 | 1 |
| piromelatine Drug Profile | 39 | 2 |
| Small Molecule to Antagonize P2X3 Receptor for Hyperalgesia Drug Profile | 41 | 1 |
| P2X Purinoceptor 3 (P2RX3) Dormant Projects | 42 | 2 |
| P2X Purinoceptor 3 (P2RX3) Discontinued Products | 44 | 1 |
| P2X Purinoceptor 3 (P2RX3) Featured News &Press Releases | 45 | 13 |
| May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference | 45 | 1 |
| May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference | 46 | 2 |
| Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference | 48 | 1 |
| Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference | 49 | 1 |
| Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial | 49 | 1 |
| Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients | 50 | 1 |
| Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial | 51 | 1 |
| Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome | 52 | 1 |
| Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet | 53 | 1 |
| Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company s Lead P2X3 Antagonist, AF-219 | 54 | 1 |
| Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia | 55 | 1 |
| Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 | 56 | 1 |
| Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes | 57 | 1 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |